课题基金 / 基金详情

Innovative growth factor functionalized products for the lifescience research market

Innovative growth factor functionalized products for the lifescience research market
适用于生命科学研究市场的创新生长因子功能化产品
批准号:
830129
负责人:
金额:
$62.46万
依托单位国家:
英国
项目类别:
Innovation Loans
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Proteins control the development and maintenance of human tissues. Using bioengineering techniques, essentially any given protein can be copied and manufactured. These purified recombinant proteins are fundamental to modern biotechnology and have many diagnostic and therapeutic applications. For example, recombinant insulin is used to treat diabetes. Recombinant proteins, especially growth factors, are also widely used in regenerative medicine research. Despite their importance, the potential utility of growth factors is critically impaired by their fragility - they break down quickly before they have achieved a useful effect. By improving stability, their medical and commercial value of can be transformed. For example, multiple injections of ordinary insulin can now be replaced by a single daily injection of stabilized insulin. Although some proteins have been stabilized, effective stabilization for most proteins remains problematic. Cell Guidance Systems has developed PODS, a “plug-and-play” platform technology which can stabilize essentially any given protein. The technology employs the unique properties of a polyhedrin protein which self-assembles into robust crystals to encase and armour the target protein. To date, we have made >95 such stabilized proteins. Here, we plan to incorporate PODS proteins into support materials to create functionalized biomaterials (bioinks, microcarriers and microspheres, and electrospun materials). These will initially be sold to the regenerative medicine research market and may ultimately be developed for therapeutic use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
  • 批准号:
    82370885
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    姚晨
  • 依托单位:
基于 Klotho 调控 FGF23/SGK1/NF-κB信号通路研究糖尿病肾病血管钙化机制及肾元颗粒干预作用
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2022
  • 负责人:
  • 依托单位:
非经典TGF-beta信号通路调控小肠干细胞稳态的作用及机制研究
mTOR信号通路关键调节蛋白Rheb临近蛋白的筛选及其在细胞衰老中的功能研究
  • 批准号:
    32070778
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2020
  • 负责人:
    吴苏
  • 依托单位: